ReviewTrends in microbiology2013
The prospects and challenges of universal vaccines for influenza.
Review in Trends in microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Advances in the Development of a Universal Influenza Vaccine.Antibodies (Basel, Switzerland) · 2026Review
- Review
- A single mutation at position 214 of influenza B hemagglutinin enhances cross-neutralization.Emerging microbes & infections · 2025Article
- mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge.PloS one · 2024Article
- Article
- Development of functional antibodies against influenza B virus by activation-induced cytidine deaminase in hybridoma cells.Virologica Sinica · 2022Article
- Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection.Vaccines · 2021Article
- Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin.Scientific reports · 2021Article
- Future epidemiological and economic impacts of universal influenza vaccines.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Isolation of Neutralizing Human Single Chain Antibodies Against Conserved Hemagglutinin Epitopes of Influenza a Virus H3N2 Strain.Reports of biochemistry & molecular biology · 2019Article
- Co-Delivery of M2e Virus-Like Particles with Influenza Split Vaccine to the Skin Using Microneedles Enhances the Efficacy of Cross Protection.Pharmaceutics · 2019Article
- Public Health-Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union.Emerging infectious diseases · 2019Article
- An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency.Theranostics · 2019Article
- Eliciting unnatural immune responses by activating cryptic epitopes in viral antigens.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Article
- Article
- Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.Antiviral research · 2017Article
- Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection.Biochemical and biophysical research communications · 2017Article
- Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets.Journal of virology · 2015Article
- Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.Biotechnology journal · 2015Review
- Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Vaccination is the most effective way to reduce the impact of epidemic as well as pandemic influenza. However, the licensed inactivated influenza vaccine induces strain-specific immunity and must be updated annually. When novel viruses appear, matched vaccines are not likely to be available in time for the first wave of a pandemic. Yet, the enormous diversity of influenza A viruses in nature makes it impossible to predict which subtype or strain will cause the next pandemic. Several recent scientific advances have generated renewed enthusiasm and hope for universal vaccines that will induce broad protection from a range of influenza viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.